Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Knockback For BMS Immunotherapy Opdivo In Lung Cancer

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibb Co.'s immunotherapy Opdivo (nivolumab) is not cost-effective and should not be provided for NHS patients with lung cancer in England and Wales, according to draft guidance from the health technology assessment body NICE. BMS had offered a confidential discounting scheme to reduce the cost below its list price of £5,200 per month (for a patient weighing 73kg), but this failed to sway the National Institute for Health and Care Excellence.

You may also be interested in...



BMS' Opdivo Is Too Expensive, Says NICE

NICE has again said no to Bristol-Myers Squibb's Opdivo, this time for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults already treated with chemotherapy. The company had suggested different pricing proposals to try and make the drug more cost-effective, but it may fare better if it focuses on certain patient populations.

Gaming Whiz Brings AI Smarts To Drug Discovery

GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.

The Top 10 Best-Selling Drugs of 2019

INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market. 

Topics

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel